Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with anti-angiogenic drugs and which will not. Massachusetts General Hospital researchers studied patients newly diagnosed with the dangerous brain tumor glioblastoma and treated with the anti-angiogenic agent cediranib. They report that those patients for whom cediranib rapidly 'normalized' abnormal blood vessels around their tumors and increased blood flow within tumors survived significantly longer than did patients in whom cediranib did not increase blood flow. Read more here.
Study mentioned: Batchelor TT, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 4. [Epub ahead of print] PMID: 24190997
No comments:
Post a Comment